Imara Announces Stockholder Approval of Merger With Enliven
22 févr. 2023 16h01 HE
|
Imara, Inc.
-- Combined Company to Trade on Nasdaq Under Ticker “ELVN” ---- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc....
Enliven Therapeutics and Imara Announce Merger Agreement
13 oct. 2022 16h35 HE
|
Imara, Inc.
Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven’s portfolio of precision oncology programsCombined company is expected to have a cash balance of...
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
05 avr. 2022 06h45 HE
|
Imara, Inc.
Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat...
Imara Reports Full Year 2021 Financial Results and Business Highlights
15 mars 2022 07h00 HE
|
Imara, Inc.
Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary...
Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights
08 mars 2022 07h00 HE
|
Imara, Inc.
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference
10 févr. 2022 07h00 HE
|
Imara, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)
25 janv. 2022 07h00 HE
|
Imara, Inc.
Expanding patient base and potential of Imara’s small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders Phase 2 trial aims to select HFpEF patients with enriched...
Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
05 janv. 2022 07h00 HE
|
Imara, Inc.
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...
Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
14 déc. 2021 07h00 HE
|
Imara, Inc.
Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261...
Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
13 déc. 2021 07h00 HE
|
Imara, Inc.
BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...